The Natural History Study of Rare Solid Tumors, currently underway at the National Cancer Institute (NCI), is enrolling patients to better understand how rare solid tumors develop and grow. Natural history studies like this will help researchers learn more about fibrolamellar carcinoma (FLC) and other rare cancers and help shape the design and development of clinical trials to test new treatment options.